Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13826 - 13850 of 14674 in total
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and
TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis).
Investigational
Matched Description: … under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and
Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder).
Investigational
Matched Description: … Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety …
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and ... CD-10* or TOP** peptidases, such as prostate cancer, colorectal cancer, melanoma, pancreatic cancer and
Investigational
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and
Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high Dose ICS-LABA).
Investigational
Matched Description: … Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and
Experimental
Investigational
Experimental
Vet approved
Cg200745 has been used in trials studying the treatment of Solid Tumour.
Investigational
AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).
Investigational
Matched Description: … AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel …
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
Investigational
Matched Description: … Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. …
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
Displaying drugs 13826 - 13850 of 14674 in total